AAP Grand Rounds Subscribe to Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stillwell, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Stillwell, P.
Related Collections
Right arrow Pulmonology

AAP Grand Rounds 2:1-2 (1999)
© 1999 American Academy of Pediatrics

PULMONOLOGY

Inhaled Glucocorticoid Therapy to Prevent BPD

Source: Cole CH, Colton T, Shah BL, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med. 1999;340:1005–1010.

The first 20% of the full text of this article appears below.

The purpose of this study was to determine if early treatment of high-risk premature infants with inhaled beclomethasone can reduce the frequency of bronchopulmonary dysplasia (BPD). The study was conducted in 3 US hospitals in Boston, Springfield, and Philadelphia using a randomized, double-blinded, placebo-controlled design. The main outcome variable was the frequency of BPD as determined by chronic supplemental O2 need and an abnormal chest radiograph at 28 days of age and 36 weeks postmenstrual age. Virtually all enrolled babies had respiratory distress syndrome, almost all were treated with surfactant replacement therapy, and about three-quarters of the mothers had received steroids. Beclomethasone, in decreasing doses from 40 to 5g per kilogram (or placebo), was administered for 4 weeks through a . . . [Full Text of this Article]

Paul Stillwell, MD, FAAP
Pediatric Pulmonology, Children’s Hospital of San Diego, San Diego, CA

 





HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Academy of Pediatrics.